How will the proliferation of specialty pharmacy products available in the marketplace be managed by payers? Precision’s Erin Lopata examines the larger role of specialty pharmacies in managing care and costs as payers work to find solutions to high pharmacy and medical spend in their specialty populations.
As the country continues to battle COVID-19, regional health plans are beginning to shift focus from pandemic response to 2021 formulary planning. While they will continue to adapt, there will undoubtedly be lasting downstream impacts and challenges from COVID-19. Erin Lopata discusses the response expected for regional health plans.
In May 2019, the FDA released guidance to clarify the level of evidence required from manufacturers to support interchangeability between a biosimilar and the reference product. Erin Lopata explains how this may impact stakeholders, and how price and utilization could be influenced by increased competition in the biologics market.